Pharmafile Logo
Pharmafocus logo
Advanced Search

Synthetic Biologics appoints Carol Reed

May 15, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Carol Reed, Synthetic

Synthetic Biologics has appointed Carol Reed as senior vice president of Clinical & Regulatory Affairs. In this position Reed will …

Appointment
Gilenya image

Gilenya to stay on US market – but with new safety warnings

May 15, 2012
Sales and Marketing EMA, FDA, Novartis, PML, gilenya

The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …

News
yervoy image

Scottish watchdog rejects Yervoy

May 14, 2012
Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma

The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy.  The SMC said that Yervoy (ipilimumab), which has …

News

New Quad HIV pill on track for FDA approval

May 14, 2012
Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad

Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group.  The US regulator is …

News
FDA picture

Obesity drugs vie for approval as FDA panel backs lorcaserin

May 14, 2012
Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity

An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …

News

BASF buys Equateq to tap into growing health ingredient business

May 11, 2012
Manufacturing and Production BASF, Equateq, Phil Taylor, omega-3

BASF has said it intends to buy Equateq, a UK-based specialist in lipid ingredients that represent a ‘global growing market’, …

News

Outsourcing on the up, but contract manufacturing still under pressure

May 11, 2012
Manufacturing and Production CMO, Jim Millar, PharmaSource, Phil Taylor, outsourcing

The pharmaceutical contract services sector experienced something for a recovery in 2011 after a lean couple of years, although the …

News

Code of Practice update to reflect legal changes

May 11, 2012
Medical Communications ABPI, Code of Practice, MHRA, PMCPA, patient organisations

The UK pharma industry’s Code of Practice is set to be updated to bring it into line with changes in …

News
NICE image

NICE changes its mind on Botox

May 11, 2012
Sales and Marketing Allergan, Botox, NHS, NICE

NICE is now recommending Allergan’s Botox for chronic migraines, reversing its previous decision.  The watchdog said in final draft guidance …

News

Gamification and online communities – what can pharma do?

May 10, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Facebook, Gamification, Syrum, digital marketing

Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This new …

Feature
neil_weir_abpi-12

ABPI appoints new Innovation Board Chair

May 10, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Neil Weir, Whitehead

The senior vice president of discovery at UCB, Neil Weir, has been appointed as the next Chair of the ABPI …

Appointment
dr_jeremy_levin_web_only

Teva appoints new president and chief executive

May 10, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Jeremy Levin, Teva

Ex-BMS head Dr Jeremy Levin has been appointed president and chief executive of Teva.  Prior to joining Teva, Levin, who …

Appointment

Patheon starts winding down Swindon operations

May 10, 2012
Manufacturing and Production CMO, Patheon, Swindon, manufacturing

North American contract manufacturer Patheon is winding down some operations at its facility in Swindon, UK, with the aim of …

News

Pfizer’s RA drug on course for approval

May 10, 2012
Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib

An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …

News

Novo Nordisk appoints ex-Pfizer head

May 10, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Pfizer, Robert Clark, regulatory affairs

Robert Clark will be joining Novo Nordisk as vice president, regulatory affairs. Clark will lead Novo Nordisk’s US regulatory team, …

Appointment
Tarceva image

Discount sways NICE into recommending Tarceva

May 10, 2012
Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer

NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease.  The watchdog said …

News
Pfizer picture

Lyrica fails in diabetes and HIV pain

May 9, 2012
Sales and Marketing Lyrica, Pfizer, neuropathic pain, pain

Two separate Phase III trials of Lyrica have failed to show benefits in treating nerve pain – one in HIV …

News

Teva appoints new president of R&D

May 9, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Michael Hayden, R&D, Teva

Teva has appointed Dr Michael Hayden as its new president of global R&D and chief scientific officer at the firm’s …

Appointment

GSK raises bid for Human Genome Services

May 9, 2012
Research and Development, Sales and Marketing GSK, Human Genome Services, bid, takeover

The latest round in GlaxoSmithKline’s attempt to take over Human Genome Services has begun with GSK appealing directly to the …

News

Celgene appoints Thomas Moriarty as general counsel

May 9, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Moriarty

Celgene has appointed Thomas Moriarty as its new general counsel and corporate secretary. In this position, he will be responsible …

Appointment
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026